GLP-1 analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-27. Anything still debated is marked as such rather than presented as settled.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Bicinchoninic acid () or BCA is a weak acid composed of two carboxylated quinoline rings. It is an organic compound with the formula (C9H5NCO2H)2. The molecule consists of a pair of quinoline rings, each bearing a carboxylic acid group. Its sodium salt forms a purple complex with cuprous ions. Bicinchoninic acid is most commonly employed in the bicinchoninic acid (BCA) assay, which is used to determine the total concentration of protein in a solution. Bicinchoninic acid is used to detect the presence of cuprous ions, due to its purple coloration via a biuret reaction. In this assay, two molecules of bicinchoninic acid chelate a single Cu+ ion, forming a purple water-soluble complex that strongly absorbs light at 562 nm.
Trump made false claims of voter fraud in the 2020 presidential election and denied the validity of the election results. In July 2024, The New York Times reported that "the Republican Party and its conservative allies are engaged in an unprecedented legal campaign targeting the American voting system", by restricting voting for partisan advantage ahead of Election Day and preparing to mount "legally dubious" challenges against the certification process if Trump were to lose. In the lead-up to the 2024 election, the Republican Party made false claims of massive "noncitizen voting" by immigrants in an attempt to delegitimize the election in the event of a Trump defeat. The claims were made as part of larger efforts within the Republican Party to disrupt the 2024 election and promote election denial. Trump and several other Republicans stated that they would not accept the results of the 2024 election if they believed they were "unfair".
EC 1.1.99.9: pyridoxine 5-dehydrogenase EC 1.1.99.10: Now EC 1.1.5.9, glucose 1-dehydrogenase (FAD, quinone) EC 1.1.99.11: Now classified as EC 1.1.5.14, fructose 5-dehydrogenase EC 1.1.99.12: sorbose dehydrogenase EC 1.1.99.13: glucoside 3-dehydrogenase EC 1.1.99.14: glycolate dehydrogenase EC 1.1.99.15: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.99.16: Now EC EC 1.1.5.4, malate dehydrogenase (quinone) EC 1.1.99.17: Now EC 1.1.5.2, quinoprotein glucose dehydrogenase EC 1.1.99.18: cellobiose dehydrogenase (acceptor) EC 1.1.99.19: Now EC 1.17.99.4, uracil/thymine dehydrogenase EC 1.1.99.20: alkan-1-ol dehydrogenase (acceptor) EC 1.1.99.21: D-sorbitol dehydrogenase (acceptor) EC 1.1.99.22: glycerol dehydrogenase (acceptor) EC 1.1.99.23: Now EC 1.1.2.6, polyvinyl alcohol dehydrogenase (cytochrome) EC 1.1.99.24: hydroxyacid-oxoacid transhydrogenase EC 1.1.99.25: Now EC 1.1.5.8, quinate dehydrogenase (quinone), EC 1.1.99.26: 3-hydroxycyclohexanone dehydrogenase EC 1.1.99.27: (R)-pantolactone dehydrogenase (flavin) EC 1.1.99.28: glucose-fructose oxidoreductase EC 1.1.99.29: pyranose dehydrogenase (acceptor) EC 1.1.99.30: 2-oxoacid reductase EC 1.1.99.31: (S)-mandelate dehydrogenase EC 1.1.99.32: L-sorbose 1-dehydrogenase EC 1.1.99.33: Now EC 1.17.99.7, formate dehydrogenase (acceptor) EC 1.1.99.34: now EC 1.1.98.2, glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.99.35: soluble quinoprotein glucose dehydrogenase EC 1.1.99.36: alcohol dehydrogenase (nicotinoprotein) EC 1.1.99.37: methanol dehydrogenase (nicotinoprotein) EC 1.1.99.38: 2-deoxy-scyllo-inosamine dehydrogenase (AdoMet-dependent) EC 1.1.99.39: D-2-hydroxyglutarate dehydrogenase EC 1.1.99.40: (R)-2-hydroxyglutarate—pyruvate transhydrogenase EC 1.1.99.41: 3-hydroxy-1,2-didehydro-2,3-dihydrotabersonine reductase EC 1.1.99.42: 4-pyridoxic acid dehydrogenase
Sources: en.wikipedia.org
== Biological carbon fixation in soils == In addition to photosynthetic and chemosynthetic processes, biological carbon fixation occurs in soil through the activity of microorganisms, such as bacteria and fungi. These soil microbes play a crucial role in the global carbon cycle by sequestering carbon from decomposed organic matter and recycling it back into the soil, thereby contributing to soil fertility and ecosystem productivity. In soil environments, organic matter derived from dead plant and animal material undergoes decomposition, a process carried out by a diverse community of microorganisms. During decomposition, complex organic compounds are broken down into simpler molecules by the action of enzymes produced by bacteria, fungi, and other soil organisms. As organic matter is decomposed, carbon is released in various forms, including carbon dioxide (CO2) and dissolved organic carbon (DOC). However, not all the carbon released during decomposition is immediately lost to the atmosphere; a significant portion is retained in the soil through processes collectively known as soil carbon sequestration. Soil microbes, mainly bacteria and fungi, play a pivotal role in this process by incorporating decomposed organic carbon into their biomass or by facilitating the formation of stable organic compounds, such as humus and soil organic matter. One key mechanism by which soil microbes sequester carbon is through microbial biomass production. Bacteria and fungi assimilate carbon from decomposed organic matter into their cellular structures as they grow and reproduce.
==== Sarcomas ==== Connective tissue malignancies, sarcomas, are rare in the oral mucosa. Osteosarcoma, chondrosarcoma arise in bone and cartilage, lymphoma in haematological disorders. The most common malignancies are carcinomas, overwhelmingly squamous cell carcinoma.
==== Social media ==== The advent of social media had a profound influence on fitness and bodybuilding. YouTube in particular has seen a surge in fitness content, ranging from gym vlogs to detailed discussions on workout attire. This not only provides consumers with an abundance of free resources to aid their fitness journey, but also creates a more informed consumer base. Another growing trend with gym-related social media is the phenomenon of gym-shaming; a video posted by content creator Jessica Fernandez on Twitch that went viral showed her lifting weights in a gym while a man in the background stared at her, sparking a widespread debate about narcissism and an increasingly toxic gym culture in the age of social media. The video led to criticism of an emerging trend in which gyms, once known as places for focused workouts, are now being treated as filming locations for aspiring or established influencers with bystanders being unintentionally placed under the public eye in the process. Bodybuilder Joey Swoll, who voiced his concerns over this culture, addressed the controversy by stating that while harassment in gyms needs to be addressed, the man in Fernandez's video was not guilty of it. Although social media is giving more attention to the world of bodybuilding, there are still some areas that are controversial. Concerns are growing over the influence bodybuilding content on social media has on young adults and their perception of their own bodies, as they often compare themselves to gym influencers online.
== Early life and education == She was born on June 26, 1946, in Manhattan, New York City. She completed her undergraduate studies in biology, cum laude in 1970 from Bryn Mawr College in Pennsylvania.
Sources: en.wikipedia.org
Small activating RNAs (saRNAs) are short double-stranded RNA molecules (typically 19–21 nucleotides in length) that induce transcriptional activation of target genes through a process known as RNA activation (RNAa). Unlike RNA interference (RNAi), which silences gene expression, saRNAs upregulate gene expression by targeting promoter regions of DNA and recruiting transcriptional machinery. The mechanism of RNAa involves the formation of an RNA-induced transcriptional activation (RITA) complex. This complex includes Argonaute proteins (particularly Ago2), RNA helicase A (RHA), and other transcriptional coactivators, which facilitate the activation of RNA polymerase II at the targeted promoter. This process is often associated with epigenetic changes, such as histone modifications, that promote active transcription. saRNAs have demonstrated potential in preclinical studies for treating diseases caused by insufficient gene expression, such as cancer and metabolic disorders. For example, saRNAs have been used to reactivate tumor suppressor genes in cancer cells, offering a promising therapeutic approach. Additionally, saRNAs are being explored for their ability to upregulate genes involved in metabolic regulation, neurodegenerative diseases, and other conditions. An example of an saRNA therapeutic in clinical development is MTL-CEBPA, which targets the CEBPA gene to treat liver cancer. This drug, developed by MiNA Therapeutics, has shown promise in early-phase clinical trials.
=== 2021–present: Post-breakup activity and abandoned fourteenth studio album === The 2021 retirement of King Crimson's "Seven-Headed Beast" line-up, and Fripp's subsequent statement that the band had finished, left a certain amount of written/performed King Crimson music unrecorded in the studio, although some of that material had appeared on live recordings from the time. New original songs performed in concert by the band had included "Meltdown", "Radical Action", "Radical Action II", "The Errors", and more. Versions of two Fripp/Jakszyk songs originally intended for King Crimson ("Uncertain Times" and "Separation") had also emerged on Jakszyk's 2020 solo album Secrets and Lies, with participation from Fripp, Harrison, Levin and Collins. Following the most recent retirement of the band, Jakko Jakszyk hinted, suggested and ultimately stated that this material will see formal release as a studio album, the band's first in over twenty years since the release of The Power to Believe. In August 2021, Jakszyk referred to the existence of "about forty to fifty minutes' worth of new (King Crimson) stuff, a number of songs I've co-written with Robert and some instrumental things he's written.
Cambridge University Press. ISBN 978-1-009-04573-5. Morano-Faodi, Sonia & Jen Neller. Fairhurst's law of the European Union, 13th edn. Harlow/NY: Pearson Education, 2020. O'Neill, Aidan (2011). EU Law for UK Lawyers (2nd ed.). Bloomsbury Publishing. ISBN 9781847318107. Reich, Norbert, Annette Nordhausen-Scholes, & Jeremy Scholes. Understanding EU internal market law, 3rd rev'd edn. Cambridge: Intersentia, 2015. Riesenhuber, Karl, ed. European legal methodology, 2nd edn. Cambridge: Intersentia, 2021. Schütze, Robert (2025). European Union Law (4th ed.). Oxford: Oxford University Press. ISBN 9780198941057. Tobler, Christa; Beglinger, Jacques (2020). Essential EU Law in Charts. Budapest HVG-ORAC. ISBN 978-963-258-489-8. Weiler, JHH (1991). "The Transformation of Europe". Yale Law Journal. 100 (8): 2403–2483. doi:10.2307/796898. ISSN 0044-0094. JSTOR 796898.
==== São Francisco River transposition and water infrastructure ==== On 9 February 2022, water from the São Francisco River transposition project reached Jardim de Piranhas in the state of Rio Grande do Norte, in the Seridó region. However, the flow lasted only 15 days, as the transposition structures had not yet been completed. Only on 13 August 2025 did the waters of the São Francisco transposition reach Rio Grande do Norte without interruption, following the completion of the works. In the state, the water flows through the bed of the Piranhas–Açu River toward the Oiticica Dam in Jucurutu and the Armando Ribeiro Gonçalves Dam between the municipalities of Açu, Itajá and São Rafael. In May 2025, a service order was signed to double the water pumping capacity across the entire Northern Axis at the pumping stations EBI1 in Cabrobó (Pernambuco), EBI2 in Terra Nova (Pernambuco), and EBI3 in Salgueiro (Pernambuco). The flow is expected to increase from 24.75 m3/s to 49 m3/s, benefiting 237 municipalities and about 8.1 million people in the states of Ceará, Pernambuco, Paraíba and Rio Grande do Norte. The project is expected to cost 491.3 million reais and to be completed in 2027. The government has also supported works on the Apodi branch in Rio Grande do Norte and the Salgado branch in Ceará, parts of the original PISF project, scheduled for completion in 2026 and 2027, as well as the Adutora da Fé in Bahia and the Canal do Sertão Baiano.
== Chemistry == Buserelin is a GnRH analogue, or a synthetic analogue of GnRH. It is a nonapeptide and is also known as [D-Ser(tBu)6,des-Gly-NH210]GnRH ethylamide or as D-Ser(tBu)6EA10-GnRH. Buserelin is marketed for medical use in both its free base (buserelin) and acetate salt (buserelin acetate) forms.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.